Small molecules & peptides
DOTA-[Pro1,Tyr4]bombesin (1-14)
Precursor for radiolabelled DOTA-[Pro1,Tyr4]bombesin (1-14)
Bombesin, 1-[1-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-; MP2346; DOTA-[P1, Y4]BBN(1-14); CA index name: Bombesin, 1-[1-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-
Sequence: DOTA-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂; DOTA = [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl; Supplied as acetate salt
Quality
Research Chemical
Characteristics
Molar mass 2042.28
CAS RN [593287-40-2] (net peptide)
Purity ≥ 95 %
- Colorless to off-white freeze-dried solid
Certificates
CoA: appearance, MS (identity), HPLC (purity)
Literature
Biddlecombe G.B. et al. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice Using ⁶⁴Cu- and ⁸⁶Y-DOTA-[Pro1,Tyr4]-Bombesin(1–14). Bioconjug Chem. 2007, 18, 724–30.
Breeman W.A. et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999, 81, 658–65.
Breeman W.A. et al. Preclinical comparison of ¹¹¹In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43, 1650–56.
Add to inquiry
| Product | Product No. | Filling amount | Quantity | ||
|---|---|---|---|---|---|
| /products/small-molecules-and-peptides/chemical/5a23fe98-5e7e-4533-9383-d5b483fc4bf0 | Precursor | Product No.: 9715 | Filling amount: 1 mg | ||
| /products/small-molecules-and-peptides/chemical/5a23fe98-5e7e-4533-9383-d5b483fc4bf0 | Precursor | Product No.: 9715 | Filling amount: 10 mg | ||
| /products/small-molecules-and-peptides/chemical/5a23fe98-5e7e-4533-9383-d5b483fc4bf0 | Precursor | Product No.: 9715 |
Product was added